Tìm theo
Ticagrelor
Các tên gọi khác (5 ) :
  • (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
  • AZD 6140
  • AZD-6140
  • AZD6140
  • Brilinta
platelet aggregation inhibitors
Thuốc Gốc
Small Molecule
CAS: 274693-27-5
ATC: B01AC24
CTHH: C23H28F2N6O4S
PTK: 522.568
Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C23H28F2N6O4S
Phân tử khối
522.568
Monoisotopic mass
522.186080514
InChI
InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
InChI Key
InChIKey=OEKWJQXRCDYSHL-FNOIDJSQSA-N
IUPAC Name
(1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Traditional IUPAC Name
ticagrelor
SMILES
CCCSC1=NC2=C(N=NN2[C@@H]2C[C@H](OCCO)[C@@H](O)[C@H]2O)C(N[C@@H]2C[C@H]2C2=CC(F)=C(F)C=C2)=N1
Độ hòa tan
10 μg/mL
logP
2.28
logS
-3.9
pKa (strongest acidic)
12.94
pKa (Strongest Basic)
2.93
PSA
138.44 Å2
Refractivity
142.13 m3·mol-1
Polarizability
51.27 Å3
Rotatable Bond Count
10
H Bond Acceptor Count
9
H Bond Donor Count
4
Physiological Charge
0
Number of Rings
5
Bioavailability
1
MDDR-Like Rule
true
Dược Lực Học : Plasma concentrations of ticagrelor are slightly increased (12–23%) in elderly patients, women, patients of Asian ethnicity, and patients with mild hepatic impairment. They are decreased in patients that described themselves as 'coloured' and such with severe renal impairment. These differences are considered clinically irrelevant. In Japanese people, concentrations are 40% higher than in Caucasians, or 20% after body weight correction. The drug has not been tested in patients with severe hepatic impairment.
Cơ Chế Tác Dụng : Ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. Unlike clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. Like the thienopyridines prasugrel, clopidogrel and ticlopidine, ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. Moreover, the drug does not need hepatic activation, which might work better for patients with genetic variants regarding the enzyme CYP2C19 (although it is not certain whether clopidogrel is significantly influenced by such variants).
Dược Động Học :
▧ Absorption :
Absorbed quickly from the gut, the bioavailability being 36%.
▧ Volume of Distribution :
The steady state volume of distribution of ticagrelor is 88 L.
▧ Protein binding :
Both ticagrelor and AR-C124910XX are bound to plasma proteins (>99.7%), and both are pharmacologically active.
▧ Metabolism :
The main metabolite, AR-C124910XX, is formed quickly via CYP3A4 by de-hydroxyethylation at position 5 of the cyclopentane ring. The metabolite reaches 30–40% of ticagrelor's plasma concentrations.
▧ Route of Elimination :
The primary route of ticagrelor elimination is hepatic metabolism. When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (58% in feces, 26% in urine).
▧ Half Life :
Ticagrelor has a half life of 7 hours, while its active metabolite has a half life of 9 hours.
Độc Tính : Bleeding is the expected pharmacologic effect of overdosing. If bleeding occurs, appropriate supportive measures should be taken. Other effects of overdose may include gastrointestinal effects (nausea, vomiting, diarrhea) or ventricular pauses.
Chỉ Định : For the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.
Tương Tác Thuốc :
  • Conivaptan CYP3A4 Inhibitors (Strong) such as conivaptan may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors.
  • Etravirine Etravirine, when used concomitantly with ritonavir boosted ticagrelor, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.
  • Lomitapide Ticagrelor increases levels of lomitapide by affecting CYP3A4 enzyme metabolism. Concomitant therapy is contraindicated.
  • Lovastatin Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects.
  • Simvastatin Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects.
Liều Lượng & Cách Dùng : Tablet - Oral - 90mg
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty : AstraZeneca
    Sản phẩm biệt dược : Brilique
  • Công ty : AstraZeneca
    Sản phẩm biệt dược : Possia
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB08816
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D09017
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0186-0777-08
Wikipedia
http://en.wikipedia.org/wiki/Ticagrelor
RxList
http://www.rxlist.com/brilinta-drug.htm
Drugs.com
http://www.drugs.com/cdi/ticagrelor.html
... loading
... loading